Quetiapine fumarate

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alcoholism

Conditions

Alcoholism, Alcohol Abuse

Trial Timeline

Dec 1, 2007 → Mar 1, 2010

NCT ID

NCT00498628

About Quetiapine fumarate

Quetiapine fumarate is a phase 2 stage product being developed by AstraZeneca for Alcoholism. The current trial status is completed. This product is registered under clinical trial identifier NCT00498628. Target conditions include Alcoholism, Alcohol Abuse.

What happened to similar drugs?

4 of 9 similar drugs in Alcoholism were approved

Approved (4) Terminated (1) Active (4)

✅Seroquel XRAstraZenecaApproved

✅Acamprosate or NaltrexoneMerckApproved

✅Acamprosate + PlaceboMerckApproved

✅LevetiracetamUCBApproved

🔄Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3

❌Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3

🔄Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00498628	Phase 2	Completed	Dec 1, 2007	Mar 1, 2010	Alcoholism
NCT00370500	Approved	Completed	Apr 1, 2007	Jul 1, 2008	Schizophrenia
NCT00326105	Phase 3	Completed	Apr 1, 2006	Jul 1, 2007	Major Depressive Disorder
NCT00326144	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Major Depressive Disorder
NCT00329264	Phase 3	Completed	Apr 1, 2006	Aug 1, 2007	Generalized Anxiety Disorder
NCT00320268	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Major Depressive Disorder
NCT00122070	Phase 3	Completed	May 1, 2005	May 1, 2008	Borderline Personality Disorder
NCT00314184	Phase 3	Completed	Mar 1, 2005	Jul 1, 2007	Bipolar Disorder
NCT00227305	Phase 3	Completed	Aug 1, 2004	Dec 1, 2007	Schizophrenia
NCT00304473	Phase 3	Completed	Aug 1, 2004	Apr 1, 2006	Schizophrenia
NCT00090311	Phase 3	Completed	Jul 1, 2004	Jul 1, 2006	Bipolar Disorder
NCT00085891	Phase 3	Completed	Jun 1, 2004	Sep 1, 2005	Schizophrenia
NCT00083954	Phase 3	Completed	Jun 1, 2004	Aug 1, 2005	Bipolar Disorder
NCT00449397	Phase 3	Completed	Jul 1, 2003	Jan 1, 2006	Psychosis

Competing Products

18 competing products in Alcoholism

See all competitors

Product	Company	Stage	Hype Score
acamprosate	Johnson & Johnson	Pre-clinical	26
Topiramate and Naltrexone	Johnson & Johnson	Phase 1	29
Topiramate	Johnson & Johnson	Phase 2	35
ondansetron + cognitive behavioral therapy + topiramate + cognitive behavioral therapy + Placebo + cognitive behavioral therapy + ondansetron + topiramate + cognitive behavioral therapy	Johnson & Johnson	Phase 2	31
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy	Johnson & Johnson	Phase 3	40
topiramate	Johnson & Johnson	Phase 2	35
Seroquel XR	AstraZeneca	Approved	43
Acamprosate or Naltrexone	Merck	Approved	43
Acamprosate + Placebo	Merck	Approved	43
SCH 900435 + Placebo	Merck	Phase 2	27
CP-866,087	Pfizer	Phase 2	35
Levetiracetam	UCB	Approved	43
levetiracetam	UCB	Phase 2	35
Nalmefene + Placebo	Lundbeck	Phase 1	18
Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mg	Alkermes	Phase 3	29
Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mg	Alkermes	Phase 3	37
Medisorb naltrexone 380 mg + Oral naltrexone 50 mg	Alkermes	Phase 3	37
Medisorb naltrexone 190 mg + Medisorb naltrexone 380 mg + Placebo matching Medisorb naltrexone 190 mg + Placebo matching Medisorb naltrexone 380 mg	Alkermes	Phase 3	37